Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil

Medical Mycology

Volumn 51, Issue 6, 2013, Pages 635-640

  Andrade Silva, Leonardo ^a   Ferreira Paim, Kennio ^a   Mora, Delio Jose ^a   Da Silva, Paulo Roberto ^a   Andrade, Anderson Assunção ^a   Araujo, Natalia Evelyn ^a   Pedrosa, André Luiz ^a   Silva Vergara, Mario León ^a  

^a Federal University of Triângulo Mineiro   (Brazil)

Author keywords

Amphotericin B; Antifungal resistance; Cryptococcus gattii; Cryptococcus neoformans; Fluconazole

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; BLOOD; BRAZIL; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CEREBROSPINAL FLUID; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SKIN DEFECT; URINE; ANTIFUNGAL SUSCEPTIBILITY; CONTROLLED STUDY; ENVIRONMENTAL FACTOR;

CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS;

EID: 84880304727     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.761737     Document Type: Article

References (44)

1. Kwon-Chung KJ, Varma A.Do major species concepts support one, two or more species within Cryptococcus neoformans ? FEMS Yeast Res 2006 ; 6: 574-587 (Pubitemid 43725741)
2. Mitchell TG, Perfect JR.Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans.Clin Microbiol Rev 1995 ; 8: 515-548
3. Stephen C, Lester S, Black W, Fyfe M, Raverty S.Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia.Can Vet J 2002 ; 43: 792-794 (Pubitemid 35314748)
4. Trilles L, Lazera Mdos S, Wanke B, et a l.Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil.Mem Inst Oswaldo Cruz 2008 ; 103: 455-462
5. Yang YL, Cheng MF, Wang CW, et a l.The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan.Med Mycol 2010 ; 48: 328-334
6. Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM.Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: Results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.Rev Iberoam Micol 2009 ; 26: 194-197
7. Garcia-Martos P, Noval JF, Garcia-Tapia A, et al.Susceptibility to antifungal agents of Cryptococcus species of clinical interest.Med Clin (Barc) 2002 ; 119: 211-213 [in Spanish] (Pubitemid 34863679)
8. Pfaller MA, Messer SA, Boyken L, et a l.G lobal trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).J Clin Microbiol 2005 ; 43: 2163-2167 (Pubitemid 40656221)
9. Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M, et al.In vitro susceptibility of Cryptococcus gattii clinical isolates.Clin Microbiol Infect 2008 ; 14: 727-730 (Pubitemid 351837036)
10. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G.Symptomatic relapse of HIV-Associated cryptococcal meningitis after initial fluconazole monotherapy: The role of fluconazole resistance and immune reconstitution.Clin Infect Dis 2006 ; 43: 1069-1073 (Pubitemid 44631110)
11. Sar B, Monchy D, Vann M, et a l.Increasing i n vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.J Antimicrob Chemother 2004; 54: 563-565 (Pubitemid 39177489)
12. De Bedout C, Ordonez N, Gomez BL, et al.In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var.neoformans and C. neoformans var. gattii.Rev Iberoam Micol 1999 ; 16: 36-39 (Pubitemid 29166856)
13. Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var.neoformans. J Antimicrob Chemother 2005 ; 56: 1144-1147 (Pubitemid 43009837)
14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard, 3rd ed.Wayne, PA: Clinical and Laboratory Standards Institute; 2008
15. Costa AK, Sidrim JJ, Cordeiro RA, et al.Urban pigeons (Columba livia) as a potential source of pathogenic yeasts: A focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil.Mycopathologia 2010 ; 169: 207-213
16. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A.Cryptococcus: From Human Pathogen to Model Yeast.Washinton, DC: ASM Press; 2010
17. Lockhart SR, Iqbal N, Bolden CB, et a l.Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: Correlation of molecular type and in vitro susceptibility.Diagn Microbiol Infect Dis 2012 ; 73: 144-148
18. Turnidge J, Kahlmeter G, Kronvall G.Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.Clin Microbiol Infect 2006; 12: 418-425
19. Larsen RA, Bauer M, Pitisuttithum P, et al.Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome.Antimicrob Agents Chemother 2005 ; 55: 5624-5630
20. Lopez-Jodra O, Torres-Rodriguez JM, Mendez-Vasquez R, et a l.In vitro susceptibility of Cryptococcus neoformans isolates to fi ve antifungal drugs using a colorimetric system and the reference microbroth method.J Antimicrob Chemother 2000 ; 45: 645-649 (Pubitemid 30255645)
21. Souza LK, Fernandes Ode F, Kobayashi CC, et al.Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city, Goias, Brazil.Rev Inst Med Trop Sao Paulo 2005 ; 47: 253-256 (Pubitemid 41565832)
22. Mora DJ, Pedrosa AL, Rodrigues V, et al.Genotype and mating type distribution within clinical Cryptococcus neoformans and Cryptococcus gattii isolates from patients with cryptococcal meningitis in Uberaba, Minas Gerais, Brazil.Med Mycol 2010 ; 48: 561-569
23. Dannaoui E, Abdul M, Arpin M, et a l.Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.Antimicrob Agents Chemother 2006 ; 50: 2464-2470 (Pubitemid 43993187)
24. Larsen RA, Bauer M, Brouwer AE, et a l.In vitro -clinical correlations for amphotericin B susceptibility in AIDS-Associated cryptococcal meningitis.Antimicrob Agents Chemother 2007 ; 51: 343-345 (Pubitemid 46047726)
25. Barchiesi F, Schimizzi AM, Caselli F, et al.Interactions between triazoles and amphotericin B against Cryptococcus neoformans.Antimicrob Agents Chemother 2000 ; 44: 2435-2441 (Pubitemid 30650892)
26. Souza LK, Souza Junior AH, Costa CR, et al.Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.Mycoses 2010 ; 53: 62-67
27. Liaw SJ, Wu HC, Hsueh PR.Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: Serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.Clin Microbiol Infect 2010 ; 16: 696-703
28. Brandt ME, Pfaller MA, Hajjeh RA, et al.Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.Antimicrob Agents Chemother 2001; 45: 3065-3069 (Pubitemid 32988829)
29. Guinea J, Hagen F, Pelaez T, et a l.Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain.Med Mycol 2010 ; 48: 942-948
30. Alves SH, Oliveira LT, Costa JM, et a l.In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil.Rev Inst Med Trop Sao Paulo 2001 ; 43: 267-270 (Pubitemid 33063714)
31. Andrade-Silva L, Ferreira-Paim K, Silva-Vergara ML, Pedrosa AL.Molecular characterization and evaluation of virulence factors of Cryptococcus laurentii and Cryptococcus neoformans strains isolated from external hospital á reas.Fungal Biol 2010 ; 114: 438-445
32. Ferreira-Paim K, Andrade-Silva L, Mora DJ, et al.Genotyping of Cryptococcus neoformans isolated from captive birds in Uberaba, Minas Gerais, Brazil.Mycoses 2011; 54: 294-300
33. Litvintseva AP, Kestenbaum L, Vilgalys R, Mitchell TG.Comparative analysis of environmental and clinical populations of Cryptococcus neoformans.J Clin Microbiol 2005 ; 43: 556-564 (Pubitemid 40256000)
34. Orni-Wasserlauf R, Izkhakov E, Siegman-Igra Y, et al.Fluconazoleresistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole.Clin Infect Dis 1999 ; 29: 1592-1593 (Pubitemid 30022776)
35. Aller AI, Claro R, Castro C, et al.Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.Chemotherapy 2007; 53: 300-305 (Pubitemid 47074654)
36. Iqbal N, DeBess EE, Wohrle R, et al.Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.J Clin Microbiol 2010 ; 48: 539-544
37. Kethireddy S Andes D.CNS pharmacokinetics of antifungal agents.Expert Opin Drug Metab Toxicol 2007 ; 3: 573-581 (Pubitemid 351324965)
38. Mondon P, Petter R, Amalfi tano G, et a l.Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.Antimicrob Agents Chemother 1999 ; 43: 1856-1861 (Pubitemid 29395175)
39. Perfect JR, Savani DV, Durack DT.Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.Antimicrob Agents Chemother 1986 ; 29: 579-583 (Pubitemid 16106374)
40. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN.Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.Diagn Microbiol Infect Dis 2011; 71: 252-259
41. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN.Echinocandin and triazole antifungal susceptibility profi les for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: Application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).Diagn Microbiol Infect Dis 2011 ; 69: 45-50
42. Trilles L, Meyer W, Wanke B, Guarro J, Lazera M.Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans / C.gattii species complex. Med Mycol 2012; 50: 328-332
43. Fernandes FLO, Passos XS, Souza LK, et al.In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiania, Brazil.Mem Inst Oswaldo Cruz 2003; 98: 839-841 (Pubitemid 38019573)
44. Silva PR, Rabelo RA, Terra AP, Teixeira DN.Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital.Rev Soc Bras Med Trop 2008 ; 41: 158-162 [in Spanish] (Pubitemid 351872395) Amparo à Pesquisa de Minas Gerais (FAPEMIG)